72 results match your criteria: "Colorado Prevention Center[Affiliation]"
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
N Engl J Med
January 2021
From Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 (P.G.S.), and Paris Sorbonne University and Groupe Hospitalier Paris Saint Joseph (M.K.), Paris; Li Ka Shing Knowledge Institute (L.A.L., S.V.) and the Divisions of Endocrinology and Metabolism (L.A.L.) and Cardiac Surgery (S.V.), St. Michael's Hospital, and the Departments of Medicine and Nutritional Sciences (L.A.L) and Surgery and Pharmacology and Toxicology (S.V.), University of Toronto, Toronto; University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) - both in Texas; Vanderbilt University, Nashville (J.B.L.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); University of Groningen-University Medical Center Groningen, Groningen, the Netherlands (A.A.V); Azienda Socio Sanitaria Territoriale Spedali Civili and University of Brescia, Brescia, Italy (M.M.); Karolinska Institutet, Stockholm (L.H.L.); Yale University, New Haven, CT (J.M.T.); Georgetown University, Washington, DC (C.S.W.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and the University of Michigan, Ann Arbor (B.P.).
Article Synopsis
- The study investigated the effects of sotagliflozin, an SGLT2 inhibitor, on patients with type 2 diabetes recently hospitalized for worsening heart failure, comparing it to a placebo.
- In the trial involving 1222 patients, those on sotagliflozin exhibited a significantly lower rate of hospitalizations and cardiovascular deaths (51.0 events per 100 patient-years) compared to the placebo group (76.3 events per 100 patient-years).
- Although sotagliflozin was found to be effective, it was associated with higher instances of diarrhea and severe hypoglycemia compared to the placebo, indicating some safety concerns.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med
January 2021
From Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael's Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women's College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto - all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) - both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) - both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.).
Article Synopsis
- - The study aimed to assess the effectiveness and safety of sotagliflozin, a sodium-glucose cotransporter 2 inhibitor, in preventing cardiovascular events in patients with type 2 diabetes and chronic kidney disease, though funding issues led to it being ended early.
- - A total of 10,584 patients were divided equally into two groups—one receiving sotagliflozin and the other a placebo—and monitored for approximately 16 months, focusing on key cardiovascular health outcomes.
- - Results indicated that the sotagliflozin group experienced fewer primary cardiovascular events (5.6 per 100 patient-years) compared to the placebo group (7.5 per 100 patient-years), but some adverse effects like diarrhea and infections
Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial.
J Am Heart Assoc
October 2020
Division of Cardiology Duke University Medical Center Durham NC.
Background There are limited data on health status instruments in patients with peripheral artery disease and cardiovascular and limb events. We evaluated the relationship between health status changes and cardiovascular and limb events. Methods and Results In an analysis of the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) trial, we examined the characteristics of 13 801 patients by tertile of health status instrument scores collected in the trial (EuroQol 5-Dimensions [EQ-5D], EQ visual analog scale [VAS], and peripheral artery questionnaire).
View Article and Find Full Text PDFClinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.
JAMA Cardiol
November 2020
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Importance: The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol management guidelines identified 2 distinct groups of patients with atherosclerotic cardiovascular disease (ASCVD) prompting different treatment recommendations.
Objective: To investigate whether the addition of high-sensitivity troponin (hsTn) testing to guideline-derived ASCVD risk can improve risk classification and downstream treatment recommendations.
Design, Setting, And Participants: A prospective cohort biomarker substudy was performed that included 8635 patients enrolled in the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
Background Current strategies for cardiovascular disease (CVD) risk assessment focus on 10-year or longer timeframes. Shorter-term CVD risk is also clinically relevant, particularly for high-risk occupations, but is under-investigated. Methods and Results We pooled data from participants in the ARIC (Atherosclerosis Risk in Communities study), MESA (Multi-Ethnic Study of Atherosclerosis), and DHS (Dallas Heart Study), free from CVD at baseline (N=16 581).
View Article and Find Full Text PDFRivaroxaban in Peripheral Artery Disease after Revascularization.
N Engl J Med
May 2020
From Colorado Prevention Center (CPC) Clinical Research (M.P.B., M.R.N., W.H.C., L.D., N.J., C.N.H., W.R.H.), the Department of Medicine, Division of Cardiovascular Medicine (M.P.B., C.N.H., W.R.H.), the Department of Surgery, Division of Vascular Surgery (M.R.N.), and the Department of Medicine, Division of Endocrinology (W.H.C.), University of Colorado Anschutz Medical Campus, and the Department of Biostatistics and Informatics, Colorado School of Public Health (J.M.K.) - all in Aurora; the Department of Vascular Medicine, Klinikum Darmstadt, Darmstadt, and Center for Thrombosis and Hemostasis, University of Mainz, Mainz (R.M.B.), the Department of Vascular Medicine, Vascular Surgery-Angiology-Endovascular Therapy, University of Hamburg-Eppendorf, Hamburg (E.S.D.), and Bayer, Wuppertal (A.F.P., E.M.) - all in Germany; the Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada (S.S.A.); Duke Clinical Research Institute, Division of Cardiology, Duke University, Durham, NC (M.R.P.); the Vascular and Interventional Radiology Department, Careggi University Hospital, University of Florence, Florence, Italy (F.F.); Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine (I.G.); B-A-Z County University Teaching Hospital, Miskolc, Hungary (L.M.); University of Latvia, Pauls Stradins University Hospital, Riga (D.K.K.); ECLA (Estudios Clínicos Latino América), ICR (Instituto Cardiovascular de Rosario), Rosario, Argentina (R.D.); the Division of Angiology, Medical University Graz, Graz, Austria (M.B.); and Janssen Research and Development, Raritan (L.P.H.), and Thrombosis Group Head, Clinical Development, Bayer U.S., Whippany (S.D.B.) - both in New Jersey.
Background: Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this context are uncertain.
Methods: In a double-blind trial, patients with peripheral artery disease who had undergone revascularization were randomly assigned to receive rivaroxaban (2.
Clinical Relevance of the 99th Percentile Upper Reference Limit for High-Sensitivity Cardiac Troponin Assays.
Clin Chem
March 2020
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas TX.
Background: The cost-effectiveness of community health worker (CHW)-based cardiovascular disease (CVD) risk-reduction interventions is not well established. Colorado Heart Healthy Solutions is a CHW-based intervention designed to reduce modifiable CVD risk factors. This program has previously demonstrated success, but the cost-effectiveness is unknown.
View Article and Find Full Text PDFIn reply to Dr. Shah and Dr. Beuhler.
Clin Toxicol (Phila)
March 2020
Division of Emergency Medicine, Duke University School of Medicine, Durham, NC, USA.
Treatment-Seeking Delay Among Hispanic and Non-Hispanic Women with Acute Myocardial Infarction.
Health Equity
June 2019
Department of Family Medicine, University of Colorado-Anschutz Medical Campus, Aurora, Colorado.
Women and minorities with acute myocardial infarction (AMI) often fail to recognize prodromal symptoms leading to delays in care. The objective of this study was to conduct a mixed method assessment of the impact of ethnicity on symptom description, recognition, and treatment-seeking behavior in Hispanic and non-Hispanic women before hospitalization for AMI. We explored differences in symptomatology, treatment-seeking behavior, and delay patterns among a convenience sample of 43 women diagnosed with AMI (17 Hispanic women, 26 non-Hispanic women) in seven rural and urban Colorado hospitals.
View Article and Find Full Text PDFMicrovascular Disease, Peripheral Artery Disease, and Amputation.
Circulation
August 2019
Division of Cardiovascular Medicine (J.A.B., M.S.D., Q.S.W., A.W.A., M.S.F.), Nashville, TN.
Background: The mechanism of adverse limb events associated with peripheral artery disease remains incompletely understood. We investigated whether microvascular disease is associated with amputation in a large cohort of veterans to determine whether microvascular disease diagnosed in any location increases the risk of amputation alone and in concert with peripheral artery disease.
Methods: Participants in the Veterans Aging Cohort Study were recruited from April 1, 2003 through December 31, 2014.
A controlled trial of mobile short message service among participants in a rural cardiovascular disease prevention program.
Prev Med Rep
March 2019
Colorado Prevention Center, Community Health Department, Aurora, CO, United States of America.
The statewide Colorado Healthy Heart Solutions (CHHS) program provides cardiovascular disease (CVD) risk factor screening and education to the medically underserved and has been shown to improve CVD risk profiles. We aimed to enhance its effectiveness through addition of a mobile health (mHealth) intervention using SMS messaging (termed Cardio SMS). We conducted a prospective, non-randomized controlled pilot trial of this intervention implemented at 5 rural program sites (number of participants = 204) compared with a contemporaneous propensity-score matched control group from 14 CHHS sites not receiving the intervention ( = 408) between 2012 and 2014.
View Article and Find Full Text PDFMedication history assessment in research: A randomized controlled trial comparing tablet-based (eMedHAT) versus structured interview (MedHAT).
Pharmacoepidemiol Drug Saf
December 2018
Rocky Mountain Poison and Drug Center, Denver Health and Hospitals, Denver, CO, USA.
Purpose: Accurate capture of medication use is important for high quality research. For epidemiologic studies, medication histories are the most common measure of exposure when trying to identify associations between medications and outcomes. Concomitant medications can alter the efficacy or safety of study drugs in clinical trials.
View Article and Find Full Text PDFReduction in Cardiovascular Risk Among Latino Participants in a Community-Based Intervention Linked With Clinical Care.
Am J Prev Med
August 2017
Colorado Prevention Center, Community Health Department, Aurora, Colorado; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Ambulatory Care Services, Denver Health and Hospital Authority, Denver, Colorado. Electronic address:
Introduction: Community Heart Health Actions for Latinos at Risk is a community health worker-led cardiovascular disease risk reduction program targeting low-income urban Latinos. The impact of community programs linked with clinical care has not been well characterized.
Methods: Community Heart Health Actions for Latinos at Risk provided 12 weeks of lifestyle education.
Health Promotion Text Messaging Preferences and Acceptability Among the Medically Underserved.
Health Promot Pract
July 2015
Center for Research in Implementation Science and Prevention, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA Denver Health and Hospital Authority, Denver, CO, USA Colorado Prevention Center, Aurora, CO, USA.
The Colorado Healthy Heart Solutions program uses community health workers to provide health promotion and navigation services for participants in medically underserved, predominantly rural areas who are at risk for developing cardiovascular disease. A text messaging program designed to increase participant engagement and adherence to lifestyle changes was pilot tested with English- and Spanish-speaking participants. Preimplementation focus groups with participants informed the development of text messages that were used in a 6-week pilot program.
View Article and Find Full Text PDFThe effect of a statewide smoking ordinance on acute myocardial infarction rates.
Am J Med
January 2014
Department of Medicine, University of Colorado Health Sciences Center, Aurora, Colo; Denver Health and the Rocky Mountain Poison and Drug Center, Denver, Colo; Colorado Prevention Center, Community Health, Aurora, Colo. Electronic address:
Background: Public smoking ordinances may reduce acute myocardial infarction events. Most studies assessed small communities with reported reductions as high as 40%. No reduction or smaller reductions were found in countrywide studies; less is known about the impact of statewide ordinances.
View Article and Find Full Text PDFThe cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
N Engl J Med
October 2013
Division of Cardiology and Colorado Prevention Center Clinical Research, Department of Medicine, University of Colorado School of Medicine, Aurora, USA.
Effectiveness of a community health worker cardiovascular risk reduction program in public health and health care settings.
Am J Public Health
January 2013
Community Health Department, The Colorado Prevention Center, Aurora, CO, USA.
Objectives: We evaluated whether a program to prevent coronary heart disease (CHD) with community health workers (CHWs) would improve CHD risk in public health and health care settings.
Methods: The CHWs provided point-of-service screening, education, and care coordination to residents in 34 primarily rural Colorado counties. The CHWs utilized motivational interviewing and navigated those at risk for CHD into medical care and lifestyle resources.
Microalbuminuria is one of the strongest predictors of both adverse renal and cardiovascular disease (CVD) outcomes in patients with type 2 diabetes mellitus. Although measurement of urinary albumin excretion (UAE) is widely recommended, limited data are available to suggest that reducing UAE translates into a reduction in long-term cardiovascular mortality, particularly among patients without overt nephropathy, who constitute most patients with type 2 diabetes worldwide. We assessed whether changes in the UAE at 1 year were associated with cardiovascular mortality in 393 patients with hypertension and type 2 diabetes during a 10-year period.
View Article and Find Full Text PDFImpact of a nurse telephone intervention among high-cardiovascular-risk, health fair participants.
J Cardiovasc Nurs
January 2010
Prevention Department, Colorado Prevention Center, University of Colorado Health Sciences Center, Denver, CO, USA.
Background And Objectives: Cardiovascular disease (CVD) is the leading cause of death in the United States, yet most individuals remain unaware of their risk. Current health fair models assess individual risk factors but miss the opportunity to assess, counsel, and follow-up with participants regarding global CVD risk. Objectives of this nurse telephone intervention were to (1) describe high-CVD-risk participants' healthcare-seeking behavior after the health fair and following a nurse telephone intervention and (2) describe CVD risk-reducing therapies provided to high-risk participants after the health fair and following a nurse telephone intervention.
View Article and Find Full Text PDFQTc interval screening in methadone treatment.
Ann Intern Med
March 2009
Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA.
Description: An independent panel developed cardiac safety recommendations for physicians prescribing methadone.
Methods: Expert panel members reviewed and discussed the following sources regarding methadone: pertinent English-language literature identified from MEDLINE and EMBASE searches (1966 to June 2008), national substance abuse guidelines from the United States and other countries, information from regulatory authorities, and physician awareness of adverse cardiac effects. RECOMMENDATION 1 (DISCLOSURE): Clinicians should inform patients of arrhythmia risk when they prescribe methadone.
Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study.
J Card Fail
May 2008
Department of Medicine, Cardiology Division at Denver Health Medical Center and the University of Colorado Health Sciences Center; Colorado Prevention Center, Denver, Colorado, USA.
Background: Predischarge beta-blocker initiation in hospitalized patients with heart failure due to reduced left ventricular ejection fraction (LVEF) is safe and improves adherence; improved outcomes with this approach have not been demonstrated in a randomized trial. This study compared 6-month rehospitalization rates among patients assigned to predischarge beta-blockade coupled with postdischarge nurse management (intervention) versus usual care.
Methods And Results: We randomized 64 patients with an LVEF View Article and Find Full Text PDF
Comparison of two point-of-care lipid analyzers for use in global cardiovascular risk assessments.
Ann Pharmacother
May 2008
Colorado Prevention Center, Denver, CO 80203, USA.
Background: Point-of-care (POC) lipid testing is increasingly used in community- and office-based practice. Two analyzers commonly used in the US are CardioChek PA and Cholestech LDX. Both directly measure total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C), mandatory values in calculating a Framingham Risk Score (FRS).
View Article and Find Full Text PDFHeart rate recovery predicts mortality and cardiovascular events in patients with type 2 diabetes.
Med Sci Sports Exerc
February 2008
University of Colorado at Denver and Health Sciences Center, Colorado Prevention Center, 789 Sherman Street, Denver, CO 80203, USA.
Purpose: Heart rate recovery (HRR) immediately after peak exercise has utility as a predictor of all-cause mortality. However, a prognostic role for HRR has not been specifically evaluated in patients with type 2 diabetes mellitus (T2DM), nor has an association between HRR and cardiovascular (CV) events been documented. This study investigated whether HRR is predictive of all-cause mortality, CV mortality, and CV events in asymptomatic patients with T2DM.
View Article and Find Full Text PDFLong-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
J Vasc Surg
February 2008
Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado School of Medicine C/O Colorado Prevention Center, Denver, CO 80203, USA.
Background: Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD). At the time of approval, the United States Food and Drug Administration required an additional long-term safety study to evaluate the effect cilostazol on mortality.
Methods: A total of 1899 subjects with a clinical diagnosis of PAD and symptoms of claudication were screened for participation in a randomized, double-blinded, placebo-controlled safety study of cilostazol.